Hi,
Anyone familiar with HKI-272 which is currently in Phase II trial? This is one of the options that was presented to my sister (stage iv) after she recently progressed on tykerb/herceptin after 4 months of stability. She has done great on it in terms of feeling good so the alternative of another bio treatment vs chemotherapy is a positive for this option. She has not done so well with side effects on prior chemo regimines.
Excerpt from
http://pubs.acs.org/cen/coverstory/84/8432cancer.html
As with Tykerb, studies of HKI-272 to date have been conducted with HER2-positive patients who have been previously treated with Herceptin. Early-phase trials have been promising. Of 23 evaluable patients in a Phase I trial to treat breast cancer, seven had confirmed partial responses, "a high rate when you consider all of these patients had multiple prior rounds of therapy, including Herceptin," Rabindran notes.
On the basis of those results, Wyeth launched Phase II trials of HKI-272 to treat metastatic breast cancer in December. The firm has yet to determine a timeline for their completion and the subsequent initiation of Phase III studies.